Measles and rubella elimination country profile: Andorra

Measles elimination status 2015 eliminated 2016 eliminated Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC) Rubella elimination status 2015 eliminated 2016 eliminated Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC) Total population 69 165 < 1 year old 618 < 5 years old 3 066 Demographic information, 2016 Source: World Population Prospects: The 2015 Revision, New York, United Nations Measles and rubella cases and immunization coverage, 2007–2016 Source:Disease incidence and immunization coverage, WHO, Data and Statistics, Immunization Monitoring and Surveilance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MCV1 = first dose of measles-containing vaccine MCV2= second dose of measles-containing vaccine Definition used for an outbreak Two or more measles or rubella cases which are temporally related and epidemiologically linked, or both Source: Measles and rubella elimination Annual Status Update report, 2016 National plan of action Does the country have a national plan of action? ND Is it updated? ND Source: Rubella Elimination Annual Status Update report, 2016 ND = Data not available Measles and rubella immunization schedule, 2016 Source: Immunization schedule, WHO, Data and Statistics, Immunization Monitoring and Surveillance (http://www.who.int/immunization/monitoring_surveillance/data/en/) MMR = measles-mumps-rubella-containing vaccine; MCV1 = first dose measles-containing vacccine; MCV2 = second dose measles-containing vaccine; RCV = rubella-containing vaccine Measles and rubella elimination country profile Andorra Information on CRS, 2016 No cases reported Source: Measles and rubella elimination Annual Status Update report, 2016 CRS = congenital rubella syndrome 0 10 20 30 40 50 60 70 80 90 100 0 5 10 15 20 25 30 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Measles Rubella Coverage MCV1 Coverage MVC2 Vaccine Schedule MCV1 MMR 1 year MCV2 MMR 3 years Year of introduction MCV2 1991 RCV 1988 Measles vaccination in school No Suspected measles cases Confirmed measles cases Discarded as non- measles Measles incidence Genotypes detected Laboratory Epi- linked Clincally Total 2012 0 0 0 0 0 0 0 NA 2013 1 0 0 0 0 1 0 NA 2014 1 0 0 0 0 1 0 NA 2015 0 0 0 0 0 0 0 NA 2016 0 0 0 0 0 0 0 NA Measles incidence, epidemiologic and virologic characteristics, 2012-2016 Measles surveillance and laboratory performance indicators, 2012-2016 Source: Measles and rubella elimination Annual Status Update report, 2012-2016 Incidence calculated per 1 million population ND = Data not available; NA= Not applicable Source: ASU 2012-2016, MeaNS 2012-2016 and laboratory accreditation results 2012-2016 ND = Data not available; NA= Not applicable A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory Rubella incidence, epidemiologic and virologic characteristics, 2012-2016 Rubella surveillance and laboratory performance indicators, 2012-2016 Source:  Measles and rubella elimination Annual Status Update report, 2012-2016 Incidence calculated per 1 million population ND = Data not available; NA= Not applicable Source: ASU 2012-2016, RubeNS 2012-2016 and laboratory accreditation results 2012-2016 ND = Data not available; NA= Not applicable A proficient laboratory is WHO accredited and/or has an established quality assurance programme with oversight by a WHO accredited laboratory Surveillance performance indicators and targets a. Rate of discarded cases: at least 2 discarded measles or rubella cases per 100 000 population b. % cases with adequate laboratory investigation: ≥ 80% c. % origin of infection known: ≥ 80% d. Rate of viral detection: ≥ 80%  Measles and rubella elimination country profile Andorra ©WHO 2018 Discarded non- measles rate % 1st sub- national unit with ≥ 2 discarded cases % cases with adequate laboratory investiga- tion % origin of infection known # specimen tested for measles % positive for measles Rate of viral detection % WHO and proficient labs 2012 NA NA NA NA 0 0 NA NA 2013 NA ND NA NA 1 0 NA NA 2014 NA ND NA NA 1 0 NA NA 2015 NA NA NA NA 0 0 NA NA 2016 NA NA NA NA 0 0 NA NA Suspected rubella cases Confirmed measles cases Discarded as non- rubella Rubella incidence Genotypes detected Laboratory Epi- linked Clincally Total 2012 0 0 0 0 0 0 0 NA 2013 0 0 0 0 0 0 0 NA 2014 0 0 0 0 0 0 0 NA 2015 0 0 0 0 0 0 0 NA 2016 0 0 0 0 0 0 0 NA Discarded non- rubella rate % 1st sub- national unit with ≥ 2 discarded cases % cases with adequate laboratory investiga- tion % origin of infection known # specimen tested for rubella % positive for rubella Rate of viral detection % WHO and proficient labs 2012 NA NA NA NA NA NA NA NA 2013 NA NA NA NA NA NA NA NA 2014 NA NA NA NA NA NA NA NA 2015 NA NA NA NA NA NA NA NA 2016 NA NA NA NA NA NA NA NA RVC comments, based on 2016 reporting The Regional Verification Commission for Measles and Rubella Elimination (RVC) concluded that endemic transmission of both measles and rubella remained interrupted in Andorra in 2016, and confirmed that measles and rubella elimina- tion has been sustained. The RVC acknowledges the country’s efforts to provide all required information in the ASU and the increase in MRCV2 coverage in 2016. The RVC urges the national health authorities to consider additional activities to further increase MRCV2 coverage. Source: Regional Verification Commission for Measles and Rubella Elimination (RVC) meeting report (www.euro.who.int/6thRVC)